PDRN for Hair Rejuvenation: Protocol and Evidence

Hair rejuvenation has become one of the most commercially significant and clinically rewarding additions to aesthetic practice menus in recent years. Patients presenting with androgenetic alopecia, diffuse hair thinning, and post-partum or stress-related hair loss are motivated, compliant, and highly loyal when treatments produce visible results. And unlike many aesthetic concerns, hair loss carries genuine psychosocial impact — patients seeking help with it are among the most grateful when effective treatment is found.

PDRN (polydeoxyribonucleotide) is one of the most evidence-supported non-surgical scalp treatments available to aesthetic practitioners. Its mechanism — adenosine A2A receptor activation driving VEGF-mediated angiogenesis and fibroblast proliferation — directly addresses the pathophysiological processes underlying the most common forms of hair thinning: follicular miniaturisation from reduced vascular supply and progressive follicle cell apoptosis. PDRN does not simply stimulate the scalp surface; it supports the biological environment in which hair follicles reside and depend.

This guide covers the complete clinical framework for PDRN scalp treatment: the hair follicle biology relevant to PDRN's mechanism, the clinical evidence, patient selection, injection protocol, combination strategies, and how Korean PDRN products — available through Celmade's PDRN and PN range — compare to PRP (platelet-rich plasma), the current market-reference comparator. For the complete PDRN/PN clinical overview, see our Complete Practitioners Guide to Polynucleotides and PDRN.

Hair Follicle Biology: What PDRN Is Targeting

To understand why PDRN works for hair rejuvenation, it is necessary to understand the biology of the hair follicle and the specific pathophysiological processes that PDRN's mechanism addresses.

The Hair Follicle Unit

Each hair follicle is a complex mini-organ consisting of several distinct cellular compartments:

•        The dermal papilla: A cluster of specialised dermal cells at the base of the follicle that govern the hair cycle — whether the follicle is in anagen (active growth), catagen (transition), or telogen (resting/shedding). Dermal papilla cells receive signals from growth factors and hormones and translate them into hair cycle regulation. Maintaining dermal papilla cell viability is fundamental to preventing follicle miniaturisation.

•        The hair matrix: The proliferating cell population immediately surrounding the dermal papilla that actively divides to produce the hair shaft. High metabolic activity makes the matrix extremely sensitive to nutritional and vascular supply.

•        The bulge region: The reservoir of hair follicle stem cells located in the mid-follicle. These stem cells repopulate the matrix at the start of each anagen phase. Depletion of the bulge stem cell pool leads to permanent follicle loss — the irreversible form of alopecia.

•        The follicular vasculature: A rich perifollicular capillary network supplies oxygen, nutrients, and growth factors to the metabolically active follicle. Impaired vascular supply — one of the primary mechanisms of androgenetic alopecia — leads to progressive follicle miniaturisation as the follicle is starved of the resources it needs to complete a full anagen cycle.

How Androgenetic Alopecia Disrupts Follicle Biology

Androgenetic alopecia (AGA — male and female pattern hair loss) is driven by androgen-mediated sensitivity at the dermal papilla, specifically through the conversion of testosterone to dihydrotestosterone (DHT) by 5-alpha-reductase. DHT binds to androgen receptors in the dermal papilla and progressively shortens the anagen phase, causing follicle miniaturisation — each successive hair cycle producing a shorter, finer hair until the follicle produces only a vellus (fine, unpigmented) hair or ceases activity entirely.

The secondary pathway — often underappreciated — is progressive impairment of perifollicular vascularity. Studies have shown significantly reduced capillary density around miniaturising follicles in AGA, compounding the DHT-mediated miniaturisation by reducing metabolic support to already-stressed follicles.

PDRN Mechanism in the Scalp: Four Pathways

PDRN's therapeutic effect in the scalp operates through four mechanisms that simultaneously address different aspects of follicle health:

Clinical Evidence for PDRN in Hair Rejuvenation

The evidence base for PDRN in hair rejuvenation has grown substantially over the past decade, with multiple controlled studies across different hair loss presentations:

Androgenetic Alopecia — Core Evidence

The most significant clinical study demonstrating PDRN efficacy for hair rejuvenation is the randomised controlled trial by Singhal et al. (2019) in the Journal of Cutaneous and Aesthetic Surgery, comparing PDRN to PRP in patients with androgenetic alopecia. The study demonstrated that PDRN produced statistically significant improvement in hair density and hair diameter at 3 and 6 months compared to baseline, with results comparable to PRP and with a better tolerability profile (less post-injection discomfort).

A further controlled study by Cervelli et al. (2014) in the BioMed Research International demonstrated significant improvement in hair growth parameters following intradermal PDRN scalp injection, with histological confirmation of increased follicle density and perifollicular vascularity in treated areas.

Korean Clinical Evidence

Korean dermatology and plastic surgery literature contains a substantial body of PDRN hair rejuvenation data, including multiple prospective studies from major academic medical centres. This evidence — accumulated over 15+ years of PDRN use in the Korean market — provides a real-world clinical dataset that far exceeds what any single published RCT can represent. Korean manufacturers' confidence in PDRN for hair rejuvenation is grounded in this depth of clinical experience.

Mechanism Validation Studies

The biological mechanisms are well-validated. Sini et al. (2005) in the Journal of Investigative Dermatology established PDRN's VEGF-mediated angiogenesis in human tissue, and multiple subsequent studies have confirmed that this angiogenic effect occurs in scalp tissue as well as other tissue types. The anti-apoptotic protection of follicle cells by A2AR activation is mechanistically supported by the broader A2AR biology literature.

Patient Selection for PDRN Hair Rejuvenation

PDRN hair rejuvenation is not appropriate for all patients presenting with hair loss — and correct patient selection is the single most important determinant of outcome satisfaction. The critical distinction is between patients with active follicles that can be stimulated and patients with permanently lost follicles where no amount of biological stimulation will produce hair growth:

Scalp PDRN Injection Protocol

The scalp injection protocol differs from facial PDRN in several important ways — primarily because the scalp is thicker, the injection target (perifollicular dermis) is slightly deeper, and the surface area being treated is significantly larger:

Equipment and Product Parameters

•        Needle gauge: 30G or 31G. Scalp skin is significantly thicker than facial skin (4–5mm total) — the slightly larger gauge allows adequate product delivery without excessive injection pressure.

•        Needle length: 4mm or 6mm. Appropriate for intradermal to subdermal scalp placement.

•        Injection angle: 30–45 degrees. Angled insertion places the needle tip at the intradermal to subdermal interface — the zone where the follicle bulge and perifollicular vasculature are located.

•        Volume per point: 0.02–0.05ml per injection point. Larger volumes per point than periorbital but comparable to standard face nappage.

•        Point spacing: 1–1.5cm across the treatment zone.

•        Total volume per session: 3–6ml for a full scalp treatment, depending on the area of concern. Focal thinning zones can be treated with less product — 2–3ml for a defined thinning area.

•        Product concentration: Standard PDRN concentration as specified by manufacturer. Higher concentration products may be appropriate for scalp use compared to periorbital — the scalp's greater tissue volume and depth tolerance makes standard full-face concentration appropriate here.

Anaesthesia Options

Scalp injections are more painful than facial injections in most patients due to the scalp's high sensory nerve density. Anaesthesia is strongly recommended and should be planned before booking the patient's first session:

•        Topical EMLA cream: Apply liberally under clingfilm occlusion to the scalp for 45–60 minutes before treatment. Less effective on scalp than on facial skin due to the hair shafts limiting complete contact, but sufficient for most patients combined with other measures.

•        Scalp nerve blocks: Infiltration of local anaesthetic along the scalp nerve distribution produces complete anaesthesia and allows comfortable, efficient treatment over the full scalp. The five scalp nerves (supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital) can be blocked at their exit points using 1–2ml of 2% lidocaine per point. This is the most effective approach for patients with low pain tolerance or for full-scalp treatment sessions.

•        Vibration analgesia: A vibrating device applied adjacent to the injection site activates the gate-control pain mechanism. Effective for reducing perceived needle pain on the scalp when combined with topical anaesthesia.

•        Ice: Less practical on the scalp than on the face due to the hair — a wrapped ice pack applied for 2 minutes before injecting each section provides some additional anaesthesia through cold desensitisation.

Step-by-Step Scalp Protocol

1.     Section the scalp: For a full scalp treatment, mentally divide the scalp into zones (frontal, vertex, temporal, occipital) and treat each zone systematically. For focal thinning, define the treatment zone before starting. Use a comb to part the hair and expose the scalp surface in each section.

2.     Clean and prepare: Wipe the treatment area with an alcohol swab or chlorhexidine solution. Allow to dry completely before injecting.

3.     Apply anaesthetic: As chosen — topical EMLA under occlusion 45–60 minutes pre-treatment, or scalp nerve block immediately before starting.

4.     Inject at intradermal to subdermal depth: Insert the needle at 30–45 degrees, advancing to the intradermal level (2–3mm in scalp skin). The needle tip should be at the level of the hair follicle bulge zone. Inject 0.02–0.05ml per point.

5.     Work systematically: Treat in rows across each zone at 1–1.5cm spacing. Maintain a consistent systematic pattern to ensure even coverage without missing areas or double-treating others.

6.     Apply gentle pressure: After each injection point, brief pressure with sterile gauze reduces localised bleeding from the scalp's rich vasculature.

7.     Complete zone coverage: Work through all planned zones before finalising the session. Total injection points for a full scalp treatment at standard spacing: 80–150 points depending on scalp size.

8.     Post-treatment: Gently cleanse any blood from the scalp surface. Advise the patient to avoid vigorous hair washing for 24 hours and to avoid heat treatments (blow-drying, straightening) for 24 hours.

Complete PDRN Hair Rejuvenation Treatment Protocol

PDRN vs PRP for Hair Rejuvenation: Clinical Comparison

PRP (platelet-rich plasma) is the most widely used comparator for PDRN in hair rejuvenation discussions. Both are evidence-supported, both stimulate follicle biology, and practitioners regularly encounter patients who have had one and are asking about the other. An honest, evidence-based comparison serves both clinical decision-making and patient consultation:

Combining PDRN with Other Hair Rejuvenation Treatments

PDRN produces its best hair rejuvenation outcomes when used as part of a coordinated multi-modal approach rather than as a standalone treatment. The most effective combinations:

•        PDRN + Minoxidil (topical): The most commonly recommended combination. Minoxidil prolongs the anagen phase and acts as a vasodilator at the scalp surface. PDRN promotes perifollicular angiogenesis from within the tissue. The two mechanisms are complementary and act at different points in follicle biology. Advise patients to continue minoxidil throughout the PDRN course — do not stop topical treatments for PDRN.

•        PDRN + Finasteride (oral): Finasteride blocks DHT conversion — addressing the androgenic driver of AGA that PDRN does not address. PDRN addresses the downstream vascular and cellular consequences. In male patients willing to use finasteride, the combination produces significantly better outcomes than either treatment alone.

•        PDRN + Low-Level Laser Therapy (LLLT): LLLT (laser caps, laser combs) stimulates follicle metabolism through photobiomodulation. Combined with PDRN's biological support, the two treatments address both the energy metabolism and the vascular/cellular environment of hair follicles. LLLT can be continued between PDRN sessions as a home treatment.

•        PDRN + Scalp microneedling (Dermaroller/Dermapen): Scalp microneedling creates controlled micro-injury that stimulates the wound healing response and may improve topical treatment penetration. Can be combined with PDRN in an alternating session schedule — microneedling at one session, PDRN injection at the next — with a minimum 2-week interval between different modality sessions.

•        PDRN + Exosomes (where available): Exosome preparations for scalp treatment are an emerging category in the UK market. The growth factor and signalling molecule content of exosomes is complementary to PDRN's mechanism. Exosome application immediately after scalp microneedling (via the channels) is an emerging combination protocol.

Setting Patient Expectations for Hair Rejuvenation Results

Hair rejuvenation is one of the most expectation-sensitive treatments in aesthetic practice. Patients present with significant distress about hair loss and often have unrealistic hope that a course of injections will restore their hair to its previous density. Managing this sensitively but honestly is essential:

•        Be specific about timeline: Hair cycles operate on a 3–6 month anagen-to-telogen schedule. Visible improvement in hair density is unlikely before 3–6 months of treatment — the new follicle activity stimulated by PDRN must complete a full anagen phase before the new hairs are visible. Patients who expect to see more hair in 4–6 weeks will be disappointed regardless of how well the treatment works.

•        Be specific about what 'success' means: For most AGA patients, success is stabilisation of further loss and some degree of improvement in density and diameter of existing hairs — not a full restoration to pre-hair loss density. For telogen effluvium, more significant recovery is achievable. Set the specific expected outcome at consultation, not after the course.

•        Use objective measures: Photograph at baseline and at each session. Trichoscopy (dermoscopy of the scalp) allows objective measurement of follicle density and hair shaft diameter that is not dependent on patient perception. Showing a patient the before-and-after trichoscopy images at the 6-month assessment — even when the improvement is subtle — provides an objective anchor for satisfaction that subjective perception alone cannot.

•        Address the whole treatment plan: PDRN works best alongside minoxidil, finasteride (where appropriate), nutritional support, and scalp health. A patient who is on the full programme is much more likely to achieve and appreciate results than one relying on PDRN alone.

Key Takeaways

•        PDRN addresses hair loss through vascular support and follicle cell protection — VEGF angiogenesis restores perifollicular blood supply, dermal papilla cell stimulation maintains follicle cycle regulation, and anti-apoptotic signalling protects bulge stem cells.

•        Best results in early to moderate AGA and telogen effluvium — follicles must still be present and at least partially active. PDRN cannot regenerate permanently lost follicles.

•        The clinical evidence is strong and growing — with head-to-head RCT data versus PRP showing comparable efficacy, and 15+ years of Korean domestic clinical use providing substantial real-world validation.

•        PDRN is operationally simpler than PRP — no blood draw, no centrifuge, consistent product, and significantly lower wholesale cost. A clinically comparable treatment with fewer logistical requirements.

•        6 induction sessions is the standard for AGA — hair biology requires more sessions than skin quality treatment. Set this expectation at the first appointment.

•        Combination with minoxidil and finasteride produces the best outcomes — PDRN addresses the vascular pathway; pharmacological treatment addresses the DHT pathway. Both together outperform either alone.

•        Korean PDRN products are appropriate for scalp treatment — CE-marked, MFDS-approved, consistent pharmaceutical-grade products in Celmade's PDRN and PN range provide a reliable, cost-effective option for practitioners building a hair rejuvenation service.

For related guides: Complete Polynucleotides and PDRN Guide, PDRN for Under-Eye Rejuvenation, and the Complete Skin Boosters Guide. Browse Celmade's PDRN and PN collection.

Frequently Asked Questions

How many PDRN sessions are needed for hair rejuvenation?

Hair rejuvenation requires more sessions than skin quality treatment because hair biology operates on a 3–6 month cycle. The standard protocol for androgenetic alopecia is 4–6 induction sessions spaced 4 weeks apart, followed by maintenance every 2–3 months. Telogen effluvium may respond with fewer sessions — 3–4 induction sessions — because the follicles are temporarily dormant rather than progressively miniaturising. Results should not be assessed before the 3–6 month mark, as this is how long it takes for a stimulated follicle to complete an anagen cycle and produce visible hair growth.

Is PDRN or PRP better for hair loss?

The head-to-head RCT by Singhal et al. (2019) showed comparable efficacy between PDRN and PRP in androgenetic alopecia at 3 and 6 months. PRP has a larger overall evidence base, including multiple systematic reviews. PDRN's advantages are operational — no blood draw or centrifuge required, consistent product quality, and significantly lower wholesale cost. For clinics without centrifuge equipment, PDRN is the most accessible evidence-supported injectable hair rejuvenation treatment available. For clinics already offering PRP, PDRN offers a complementary or alternative option for patients who cannot receive autologous treatment.

Can PDRN regrow hair in a completely bald area?

No — PDRN stimulates and supports follicles that are still present and at least partially active. In areas where follicles have been permanently lost (producing no vellus or terminal hairs), there is nothing left to stimulate. PDRN is most effective in areas showing active miniaturisation — where vellus hairs are present or where density has decreased but follicles are still visible on dermoscopy. Complete baldness in an area for more than 5–7 years typically indicates permanent follicle loss and is not appropriate for injectable hair rejuvenation.

Should patients stop minoxidil or finasteride before PDRN treatment?

No — patients should continue their existing hair loss medications throughout the PDRN course. Minoxidil and finasteride address different mechanisms (surface vasodilation and DHT suppression respectively) and their discontinuation could accelerate hair loss during the PDRN course. PDRN's mechanism does not interact negatively with either medication. The combination of pharmacological treatment and PDRN typically produces better outcomes than PDRN alone.

Is PDRN hair treatment appropriate for women?

Yes — female pattern hair loss (Ludwig pattern AGA) responds to PDRN through the same mechanisms as male AGA. The vascular support and follicle cell protection of PDRN are equally relevant in female pattern hair loss. The treatment protocol is the same. Finasteride is not used for female AGA (due to hormonal effects) but minoxidil can be continued alongside PDRN. Post-partum telogen effluvium — one of the most common hair loss presentations in women — responds particularly well to PDRN, with the follicle recovery mechanism providing excellent support during what would otherwise be a self-resolving but prolonged recovery.